TLSA

Healthcare Biotechnology

Tiziana Life Sciences Ltd

$1.12

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

142.53M

Avg Volume

704,704

EPS

-$0.16

52W High

$2.33

52W Low

$0.76

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-5.61

EV/EBITDA

-6.22

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(924.3%)

Return on Assets

(116.0%)

Liquidity & Leverage

Current Ratio

0.76

Quick Ratio

0.72

Debt / Equity

8.77

Total Cash

4.01M

Total Debt

456,000

About

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.